Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care...

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer - PressReach

Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … …

Incyte (INCY) Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus

Incyte (NasdaqGS: INCY) and Genmab agreed a new clinical trial collaboration to study treatments for KRAS G12D-mutated metastatic colorectal cancer. The partnership will combine Incyte's selective KRAS G12D inhibitor candidate INCB161734 with Genmab's investigational bispecific antibody petosemtamab. The collaboration focuses on patients with KRAS G12D-mutated metastatic colorectal cancer, an area where treatment options remain limited. The new …

Genmab and Incyte agree to colorectal cancer trial

Genmab will run a Phase 1/2 trial of petosemtamab, Incyte’s KRAS G12D inhibitor and chemotherapy; trial timing and endpoints remain undisclosed.

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer